Vitamin D sterol/VDR conformational dynamics and nongenomic actions

Vitamin D

Volumn , Issue , 2011, Pages 271-297

  Mizwicki, Mathew T ^a   Norman, Anthony W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865313960     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10015-0     Document Type: Chapter

References (192)

1. Mizwicki M.T., Norman A.W. The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci. Signal 2009, 2:re.4.
2. Norman A.W., Mizwicki M.T., Norman D.P.G. Steroid hormone rapid actions, membrane receptors and a conformational ensemble model. Nature Reviews Drug Discovery 2004, 3:27-41.
3. Fleet J.C. Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean?. J. Nutr. 2004, 134:3215-3218.
4. 3 mediated rapid and genomic responses in NB4 cells: evidence for cross-talk from rapid responses to genomic effects. Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects 2000, University of California, Riverside, Riverside, CA, 691-698.
5. Narayanan R., Sepulveda V.A., Falzon M., Weigel N.L. The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J. Biol. Chem. 2004, 279:47298-47310.
6. 3-mediated vesicular transport of calcium in intestine: time course studies. Endocrinology 1988, 122:2962-2969.
7. Whitfield G.K., Jurutka P.W., Haussler C.A., Hsieh J.-C., Barthel T.K., Jacobs E.T., et al. Nuclear vitamin D receptor: structure-function, molecular control of gene transcription and novel bioactions. Vitamin D 2005, 219-328. Elsevier Academic Press, San Diego. second ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
8. Pike J.W., Meyer M.B., Watanuki M., Kim S., Zella L.A., Fretz J.A., et al. Perspectives on mechanisms of gene regulation by 1,25-dihydroxyvitamin D3 and its receptor. J. Steroid Biochem. Mol. Biol. 2007, 103:389-395.
9. Barsony J., Renyi I., McKoy W. Subcellular distribution of normal and mutant vitamin D receptors in living cells - studies with a novel fluorescent ligand. J. Biol. Chem. 1997, 272:5774-5782.
10. Klopot A., Hance K.W., Peleg S., Barsony J., Fleet J.C. Nucleo-cytoplasmic cycling of the vitamin D receptor in the enterocyte-like cell line, Caco-2. J. Cell Biochem. 2007, 100:617-628.
11. 3in vivo and in vitro. Mol. Endocrinol. 2004, 18:2660-2671.
12. Silvagno F., Poma C.B., Realmuto C., Ravarino N., Ramella A., Santoro N., et al. Analysis of vitamin D receptor expression and clinical correlations in patients with ovarian cancer. Gynecol. Oncol. 2010, 119:121-124.
13. Silvagno F., De V.E., Attanasio A., Gallo V., Mazzucco G., Pescarmona G. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLoS. ONE 2010, 5:e.8670.
14. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 1995, 16:200-257.
15. Okamura W.H., Zhu G.-D. Chemistry and Design: Structural Biology of Vitamin D Action. Vitamin D 1997, 939-971. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
16. 3: analogs are able to functionally differentiate between nuclear and membrane receptors. Biochem. Biophys. Res. Commun. 1994, 201:394-401.
17. 3 act as agonists for two different receptors in the vitamin D endocrine system to mediate tenomic and rapid responses. Steroids 2001, 66:147-158.
18. 3 stimulated transcaltachia (the rapid hormonal stimulation of intestinal calcium transport). Biochem. Biophys. Res. Commun. 1992, 189:1450-1456.
19. 3 based on the provitamin D skeleton. Annals N.Y. Acad. Sci. 1995, 761:344-348.
20. Okamura W.H., Do S., Holm K., Tan E., Tham F., Jeganathan S., et al. Constitutional and conformational isomers of 1α,25-dihydroxyvitamin D3 and its metabolites. Vitamin D Endocrine System 2000, Structural, Biological, Genetic and Clinical Aspects. Riverside, CA: University of California, Riverside; 11-22.
21. Norman A.W., Mizwicki M.T., Okamura W.H. Ligand structure-function relationships in the vitamin D endocrine system from the perspective of drug development (including cancer treatment). Recent Results Cancer Res. 2003, 164:55-82.
22. Havinga E., De Kock R.J., Rappoldt M.P. The photochemical interconversions of provitamin D, lumisterol, previtamin D and tachysterol. Tetrahed. Lett. 1960, 11:276-284.
23. 3. Tetrahed. Lett. 1975, 261-264.
24. Sheves M., Mazur Y. The vitamin D-3,5-cyclovitamin D rearrangement. J. Am. Chem. Soc. 1975, 97:6249-6250.
25. 3. J. Am. Chem. Soc. 1978, 100:5626-5634.
26. ?-sigmatropic hydrogen shifts - stereochemistry, kinetics, isotope effects, and PI-facial selectivity. J. Am. Chem. Soc. 1987, 109:4690-4698.
27. 3, the plasma vitamin D binding protein, and their ligands. J. Bone. Miner. Res. 2003, 18:795-806.
28. Okamura W.H., Norman A.W., Wing R.M. Vitamin D: concerning the relationship between molecular topology and biological function. Proc. Natl. Acad. Sci. USA 1974, 71:4194-4197.
29. 13]C-labeled vitamin D metabolites. J. Org. Chem. 2002, 67:1637-1650.
30. Mizwicki M.T., Bula C.M., Bishop J.E., Norman A.W. A perspective on how the vitamin D sterol/vitamin D receptor (VDR) conformational ensemble model can potentially be used to understand the structure-function results of A-ring modified vitamin D sterols. J. Steroid Biochem. Mol. Biol. 2005, 97:69-82.
31. 3 with 20-cyclopropyl-modified side-chains: implications for ligand binding and calcemic properties. J. Steroid Biochem. Mol. Biol. 2004, 89-90:99-106.
32. Mizwicki M.T., Bula C.M., Bishop J.E., Norman A.W. New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model. J. Steroid Biochem. Mol. Biol. 2007, 103:243-262.
33. Yamada S., Nakayama K., Takayama H., Itai A., Iitaka Y. Studies of vitamin D oxidation. 3. Dye-sensitized photooxidation of vitamin D and chemical behavior of vitamin D 6,19-epidioxides. J. Org. Chem. 1983, 48:3477-3483.
34. 3: synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. J. Med. Chem. 2002, 45:3366-3380.
35. 3-24R-hydroxy lase: a catabolic or biosynthetic enzyme?. Steroids 2001, 66:391-398.
36. Midland M.M., Plumet J., Okamura W.H. Effect of C20 stereochemistry on the conformational profile of the side chains of vitamin D analogs. Bioorg. Med. Chem. Lett. 1993, 3:1799-1804.
37. 3 signaling. Proc. Natl. Acad. Sci. USA 2004, 101:12876-12881.
38. Mizwicki M.T., Bishop J.E., Norman A.W. Applications of the vitamin D sterol-Vitamin D receptor (VDR) conformational ensemble model. Steroids 2005, 70:464-471.
39. Yamada S., Yamamoto K., Masuno H., Ohta M. Conformation-function relationship of vitamin D: conformational analysis predicts potential side-chain structure. J. Med. Chem. 1998, 41:1467-1475.
40. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell 2000, 5:173-179.
41. Tocchini-Valentini G., Rochel N., Wurtz J.M., Mitschler A., Moras D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. USA 2001, 98:5491-5496.
42. 3 are associated with enhanced activation of the vitamin D receptor. J. Biol. Chem. 1995, 270:10551-10558.
43. 3 analogues and their 20- epi homologues with the vitamin D receptor. J. Biol. Chem. 1997, 272:3336-3345.
44. Mizwicki M.T., Bula C.M., Mahinthichaichan P., Henry H.L., Ishizuka S., Norman A.W. On the mechanism underlying (23S)-25-dehydro-1{alpha}(OH)-vitamin D3-26,23-lactone antagonism of hVDRwt gene activation and its switch to a superagonist. J. Biol. Chem. 2009, 284:36292-36301.
45. Mizwicki M.T., Menegaz D., Yaghmaei S., Henry H.L., Norman A.W. A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure-function implications. J. Steroid Biochem. Mol. Biol. 2010, 121:98-105.
46. 3 autoregulation in keratinocytes. J. Biol. Chem. 2002, 277:36987-36990.
47. Brown A.J., Ritter C.S., Weiskopf A.S., Vouros P., Sasso G.J., Uskokovic M.R., et al. Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion. J. Cell Biochem. 2005, 96:569-578.
48. 3 in two rat osteosarcoma cell lines (umr 106 and ros 17/2.8): existence of the C-3 epimerization pathway independent of the C-24 oxidation pathway. Bone 1999, 24/5:457-463.
49. 3 in rats. FEBS. Lett. 1999, 448:278-282.
50. Sheves M., Berman E., Freeman D., Mazur Y. Conformation equilibria in vitamins D. The synthesis of 1α-hydroxy-3-epivitamin D3 (1α-hydroxy-2A-cholecalciferol). J. C. S. Chem. Comm. 1975, 511:643-644.
51. 3. J. Org. Chem. 1977, 42:3597-3599.
52. Kamao M., Tatematsu S., Sawada N., Sakaki T., Hatakeyama S., Kubodera N., et al. Cell specificity and properties of the C-3 epimerization of Vitamin D(3) metabolites. J. Steroid Biochem. Mol. Biol. 2004, 89-90:39-42.
53. Bischof M.G., Siu-Caldera M.L., Weiskopf A., Vouros P., Cross H.S., Peterlik M., et al. Differentiation-related pathways of 1α,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1α,25-dihydroxy-3epi-cholecalciferol. Exp. Cell Res. 1998, 241:194-201.
54. 3 mediated rapid and genomic responses are dependent upon critical structure-function relationships for both the ligand and receptor(s). Vitamin D 2005, 381-407. Elsevier Academic Press, San Diego. second ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
55. Verboven C., Rabijns A., De Maeyer M., Van Baelen H., Bouillon R., De Ranter C. A structural basis for the unique binding features of the human vitamin D-binding protein. Nat. Struct. Biol. 2002, 9:131-136.
56. 3. Biochem. Biophys. Res. Commun. 1974, 60:179-185.
57. 3: its synthesis and conformational analysis. Tetrahed. Lett. 1975, 49:4317-4320.
58. 3 is independent of nuclear receptor binding. J. Biol. Chem. 1995, 270:15962-15965.
59. Takito J., Shinki T., Sasaki T., Suda T. Calcium uptake by brush-border and basolateral membrane vesicles in chick duodenum. Am. Physiol. Soc. 1990, G16-G23.
60. 3 requires the presence of a functional vitamin D nuclear receptor. Proc. Natl. Acad. Sci. USA 2004, 101:1589-1594.
61. Biswas P., Zanello L.P. 1alpha,25(OH)(2) vitamin D(3) induction of ATP secretion in osteoblasts. J. Bone Miner Res. 2009, 24:1450-1460.
62. Bravo S., Paredes R., Izaurieta P., Lian J.B., Stein J.L., Stein G.S., et al. The classic receptor for 1Alpha,25-dihydroxy vitamin D3 is required for non-genomic actions of 1alpha,25-dihydroxy vitamin D3 in osteosarcoma cells. J. Cell Biochem. 2006, 99:995-1000.
63. Menegaz D., Barrientos-Duran A., Kline A., Silva F.R., Norman A.W., Mizwicki M.T., et al. 1Alpha,25(OH)(2)-vitamin D(3) stimulation of secretion via chloride channel activation in Sertoli cells. J. Steroid Biochem. Mol. Biol. 2010, 119:127-134.
64. Norman A.W., Bouillon R. Vitamin D nutritional policy needs a vision for the future. Exp. Biol. & Med. 2010, 235:1034-1045.
65. Bouillon R., Norman A.W., Lips P. Vitamin D deficiency. New Engl. J. Med. 2007, 357:1980-1982.
66. Peng X., Hawthorne M., Vaishnav A., St-Arnaud R., Mehta R.G. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res. Treat. 2009, 113:31-41.
67. Lou Y.R., Molnar F., Perakyla M., Qiao S., Kalueff A.V., St-Arnaud R., et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J. Steroid Biochem. Mol. Biol. 2010, 118:162-170.
68. Hamill O.P., Huguenard J.R., Prince D.A. Patch-clamp studies of voltage-gated currents in identified neurons of the rat cerebral cortex. Cereb. Cortex 1991, 1:48-61.
69. Jentsch T.J., Stein V., Weinreich F., Zdebik A.A. Molecular structure and physiological function of chloride channels. Physiol. Rev. 2002, 82:503-568.
70. Jentsch T.J. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit. Rev. Biochem. Mol. Biol. 2008, 43:3-36.
71. Alekov A.K., Fahlke C. Anion channels: regulation of ClC-3 by an orphan second messenger. Curr. Biol. 2008, 18:R1061-R1064.
72. 3 induction of ATP secretion in osteoblasts. J. Bone Miner Res. 2009, 24:1450-1460.
73. Bettoun D.J., Buck D.W., Lu J., Khalifa B., Chin W.W., Nagpal S. A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J. Biol. Chem. 2002, 277:24847-24850.
74. Bettoun D.J., Lu J., Khalifa B., Yee Y., Chin W.W., Nagpal S. Ligand modulates VDR-Ser/Thr protein phosphatase interaction and p70S6 kinase phosphorylation in a cell-context-dependent manner. J. Steroid Biochem. Mol. Biol. 2004, 89-90:195-198.
75. Hagner P.R., Schneider A., Gartenhaus R.B. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010, 115:2127-2135.
76. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci. STKE. 2005, 2005:e.4.
77. He P., Klein J., Yun C.C. Activation of Na+/H+ exchanger NHE3 by angiotensin II is mediated by inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with IP3 (IRBIT) and Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 2010, 285:27869-27878.
78. Devogelaere B., Beullens M., Sammels E., Derua R., Waelkens E., van Lint J., et al. Protein phosphatase-1 is a novel regulator of the interaction between IRBIT and the inositol 1,4,5-trisphosphate receptor. Biochem. J. 2007, 407:303-311.
79. Stables M.J., Gilroy D.W. Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. Jul. 2010, 23. In press.
80. 3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases. J. Biol. Chem. 2005, 280:14130-14137.
81. Zhang X., Zanello L.P. Vitamin D receptor-dependent 1alpha,25(OH)(2) vitamin D3-induced antiapoptotic PI3K/Akt signaling in osteoblasts. J. Bone Miner. Res. 2008, 23:1238-1248.
82. von Essen M.R., Kongsbak M., Schjerling P., Olgaard K., Odum N., Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat. Immunol. 2010, 11:344-349.
83. Liu W., Asa S.L., Ezzat S. 1Alpha,25-dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol. Endocrinol. 2005, 19:2349-2357.
84. Zinser G.M., Welsh J. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 2004, 25:2361-2372.
85. Pan L., Matloob A.F., Du J., Pan H., Dong Z., Zhao J., et al. Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulation. FEBS J. 2010, 277:989-999.
86. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol. Cell Endocrinol. 2010, 321:103-111.
87. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol. Metab. Clin. North Am. 2010, 39:365-379.
88. Hsieh J.-C., Jurutka P.W., Galligan M.A., Terpening C.M., Haussler C.A., Samuels D.S., et al. Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function. Proc. Natl. Acad. Sci. USA 1991, 88:9315-9319.
89. Haussler M.R., Jurutka P.W., Hsieh J.-C., Thompson P.D., Haussler C.A., Selznick S.H., et al. Nuclear vitamin D receptor: structure-function, phosphorylation, and control of gene expression. Vitamin D 1997, 149-177. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
90. Hsieh J.C., Dang H.T., Galligan M.A., Whitfield G.K., Haussler C.A., Jurutka P.W., et al. Phosphorylation of human vitamin D receptor serine-182 by PKA suppresses 1,25(OH)2D3-dependent transactivation. Biochem. Biophys. Res. Commun. 2004, 324:801-809.
91. Jurutka P.W., Hsieh J.C., Nakajima S., Haussler C.A., Whitfield G.K., Haussler M.R. Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. Proc. Natl. Acad. Sci. USA 1996, 93:3519-3524.
92. Norman A.W., Ishizuka S., Okamura W.H. Ligands for the vitamin D endocrine system: different shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand for the plasma vitamin D binding protein. J. Steroid Biochem. Mol. Biol. 2001, 76:49-59.
93. Peric M., Koglin S., Dombrowski Y., Gross K., Bradac E., Buchau A., et al. Vitamin D analogs differentially control antimicrobial peptide/"alarmin" expression in psoriasis. PLoS ONE 2009, 4:e.6340.
94. 2+ concentration in pancreatic β-cells through nongenomic signal transduction. Endocrinology 1999, 140:4706-4712.
95. 3 evokes oscillations of intracellular calcium in a pancreatic β-cell line. Endocrinology 1995, 136:2852-2861.
96. Guzey M., Kitada S., Reed J.C. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol. Cancer Ther. 2002, 1:667-677.
97. Malloy P.J., Feldman D. Inactivation of the human vitamin D receptor by caspase-3. Endocrinology 2009, 150:679-686.
98. Masoumi A., Goldenson B., Ghirmai S., Avagyan H., Zaghi J., Abel K., et al. 1Alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J. Alzheimers. Dis. 2009, 17:703-717.
99. 3 is associated with an increase in p53 and a decrease in nitric oxide products. J. Invest. Dermatol. 2007, 127:707-715.
100. Mason R.S., Sequeira V.B., Dixon K.M., Gordon-Thomson C., Pobre K., Dilley A., et al. Photoprotection by 1alpha,25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J. Steroid Biochem. Mol. Biol. 2010, 121:164-168.
101. 3 is present in an intestinal caveolae membrane fraction. Biochem. Biophys. Res. Commun. 2002, 298:414-419.
102. Nemere I., Hintze K. Novel hormone "receptors". J. Cell Biochem. 2008, 103:401-407.
103. Farach-Carson M.C., Nemere I. Membrane receptors for vitamin D steroid hormones: potential new drug targets. Curr. Drug. Targets 2003, 4:67-76.
104. Mesbah M., Nemere I., Papagerakis P., Nefussi J.R., Orestes-Cardoso S., Nessmann C., et al. Expression of a 1,25-dihydroxyvitamin D3 membrane-associated rapid-response steroid binding protein during human tooth and bone development and biomineralization. J. Bone Miner. Res. 2002, 17:1588-1596.
105. Boyan B.D., Sylvia V.L., Dean D.D., Pedrozo H., Del T.F., Nemere I., et al. 1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and PGE2. Steroids 1999, 64:129-136.
106. Chen J., Olivares-Navarrete R., Wang Y., Herman T.R., Boyan B.D., Schwartz Z. Protein disulfide isomerase associated 3 (Pdia3) mediates the membrane response to 1,25-dihydroxy vitamin D3 in osteoblasts. J. Biol. Chem. Sept. 2010, 15. In press.
107. Nemere I., Safford S.E., Rohe B., DeSouza M.M., Farach-Carson M.C. Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS) binding protein. J. Steroid Biochem. Mol. Biol. 2004, 89-90:281-285.
108. Khanal R.C., Nemere I. The ERp57/GRp58/1,25D3-MARRS receptor: multiple functional roles in diverse cell systems. Curr. Med. Chem. 2007, 14:1087-1093.
109. Tunsophon S., Nemere I. Protein kinase C isotypes in signal transduction for the 1,25D3-MARRS receptor (ERp57/PDIA3) in steroid hormone-stimulated phosphate uptake. Steroids 2010, 75:307-313.
110. Wu W., Beilhartz G., Roy Y., Richard C.L., Curtin M., Brown L., et al. Nuclear translocation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NFkappaB in differentiating NB4 leukemia cells. Exp. Cell Res. 2010, 316:1101-1108.
111. Chidlow J.H., Sessa W.C. Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc. Res. 2010, 86:219-225.
112. Zhao G., Simpson R.U. Membrane localization, caveolin-3 association and rapid actions of vitamin D receptor in cardiac myocytes. Steroids 2010, 75:555-559.
113. Hansen C.G., Nichols B.J. Exploring the caves: cavins, caveolins and caveolae. Trends. Cell Biol. 2010, 20:177-186.
114. Yao Z., Seger R. The ERK signaling cascade - views from different subcellular compartments. Biofactors 2009, 35:407-416.
115. Patra S.K. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim. Biophys. Acta. 2008, 1785:182-206.
116. Krajewska W.M., Maslowska I. Caveolins: structure and function in signal transduction. Cell Mol. Biol. Lett. 2004, 9:195-220.
117. Buitrago C., Boland R. Caveolae and caveolin-1 are implicated in 1alpha,25(OH)(2)-vitamin D(3)-dependent modulation of Src, MAPK cascades and VDR localization in skeletal muscle cells. J. Steroid Biochem. Mol. Biol. 2010, 121:169-175.
118. 3. Biochem. Biophys. Res. Commun. 2001, 289:1150-1156.
119. Li S., Couet J., Lisanti M.P. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem. 1996, 271:29182-29190.
120. Rosner M., Hanneder M., Siegel N., Valli A., Hengstschlager M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat. Res. 2008, 658:234-246.
121. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 2003, 13:1259-1268.
122. Hoyer-Hansen M., Bastholm L., Szyniarowski P., Campanella M., Szabadkai G., Farkas T., et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol. Cell 2007, 25:193-205.
123. Means A.R. The year in basic science: calmodulin kinase cascades. Mol. Endocrinol. 2008, 22:2759-2765.
124. Orlova K.A., Crino P.B. The tuberous sclerosis complex. Ann. N.Y. Acad. Sci. 2010, 1184:87-105.
125. Levin E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab. 2009, 20:477-482.
126. Levin E.R. Membrane oestrogen receptor alpha signalling to cell functions. J. Physiol. 2009, 587:5019-5023.
127. Bartik L., Whitfield G.K., Kaczmarska M., Lowmiller C.L., Moffet E.W., Furmick J.K., et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J. Nutr. Biochem. Feb. 2010, 21:1153-1161.
128. Jurutka P.W., Bartik L., Whitfield G.K., Mathern D.R., Barthel T.K., Gurevich M., et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J. Bone Miner. Res. 2007, 22(Suppl. 2):V2-10.
129. Krylova I.N., Sablin E.P., Moore J., Xu R.X., Waitt G.M., MacKay J.A., et al. Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell 2005, 120:343-355.
130. 3 require the VDR and influence 24-hydroxylase activity: studies in human skin fibroblasts bearing vitamin D receptor mutations. J. Biol. Chem. 2004, 279:7591-7597.
131. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXRα. Nature 1995, 375:377-382.
132. Vivat V., Zechel C., Wurtz J.M., Bourguet W., Kagechika H., Umemiya H., et al. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers. EMBO J. 1997, 16:5697-5709.
133. Bourguet W., Vivat V., Wurtz J.M., Chambon P., Gronemeyer H., Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand- binding domains. Mol. Cell 2000, 5:289-298.
134. Weatherman R.V., Fletterick R.J., Scanlon T.S. Nuclear receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 1999, 68:559-582.
135. Sutton A.L., MacDonald P.N. Vitamin D: more than a 'bone-a-fide' hormone. Mol. Endocrinol. 2003, 17:777-791.
136. Zhang J., Chalmers M., Stayrook K., Burris L., Garcia-Ordonez R., Pascal B., et al. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure 2011, 18:1332-1341.
137. Sicinska W., Westler W.M., DeLuca H.F. NMR assignments of tryptophan residue in apo and holo LBD-rVDR. Proteins 2005, 61:461-467.
138. Smock R.G., Gierasch L.M. Sending signals dynamically. Science 2009, 324:198-203.
139. 3 receptor (VDR) to the ligand cause significant transactivational effects. J. Steroid Biochem. Mol. Biol. 2007, 103:286-292.
140. 3: past, present, and future. J. Bone Miner. Res. 1998, 13:1360-1369.
141. 3-26-23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change. Mol. Endocrinol. 2000, 14:1788-1796.
142. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 1994, 84:1960-1967.
143. Kakuda S., Ishizuka S., Eguchi H., Mizwicki M.T., Norman A.W., Takimoto-Kamimura M. Structural basis of the histidine-mediated vitamin D receptor agonistic and antagonistic mechanisms of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone. Acta. Crystallogr. D. Biol. Crystallogr. 2010, 66:918-926.
144. Nguyen T.M., Adiceam P., Kottler M.L., Guillozo H., Rizk-Rabin M., Brouillard F., et al. Tryptophan missense mutation in the ligand-binding domain of the vitamin D receptor causes severe resistance to 1,25-dihydroxyvitamin D. J. Bone Miner. Res. 2002, 17:1728-1737.
145. Demay M.B., MacDonald P.N., Skorija K., Dowd D.R., Cianferotti L., Cox M. Role of the vitamin D receptor in hair follicle biology. J. Steroid Biochem. Mol. Biol. 2007, 103:344-346.
146. Cianferotti L., Cox M., Skorija K., Demay M.B. Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc. Natl. Acad. Sci. USA 2007, 104:9428-9433.
147. Swann S.L., Bergh J., Farach-Carson M.C., Ocasio C.A., Koh J.T. Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. J. Am. Chem. Soc. 2002, 124:13795-13805.
148. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
149. Cohen-Lahav M., Douvdevani A., Chaimovitz C., Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J. Steroid Biochem. Mol. Biol. 2007, 103:558-562.
150. Poylin V., Fareed M.U., O'Neal P., Alamdari N., Reilly N., Menconi M., et al. The NF-kappaB inhibitor curcumin blocks sepsis-induced muscle proteolysis. Mediators Inflamm. 2008, 2008:317851.
151. Maitra R., Porter M.A., Huang S., Gilmour B.P. Inhibition of NFkappaB by the natural product Withaferin A in cellular models of cystic fibrosis inflammation. J. Inflamm. (Lond.) 2009, 6:15.
152. 3 modulates human adipocyte metabolism via nongenomic action. FASEB J. 2001, 15:2751-2753.
153. 3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ. Res. 2002, 91:17-24.
154. Morelli A., Squecco R., Failli P., Filippi S., Vignozzi L., Chavalmane A.K., et al. The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder. Am. J. Physiol. Cell Physiol. 2008, 294:C1206-C1214.
155. Tishkoff D.X., Nibbelink K.A., Holmberg K.H., Dandu L., Simpson R.U. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008, 149:558-564.
156. Ordonez-Moran P., Larriba M.J., Palmer H.G., Valero R.A., Barbachano A., Dunach M., et al. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J. Cell Biol. 2008, 183:697-710.
157. Cui M., Zhao Y., Hance K.W., Shao A., Wood R.J., Fleet J.C. Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2. J. Cell Physiol. 2009, 219:132-142.
158. 2+. Am. J. Physiol. 1994, G465-G475.
159. 3 stimulates phospholipase C-γ in rat colonocytes: role of c-Src in PLC-gamma activation. J. Clin. Invest. 1997, 99:1831-1841.
160. Ellison T.I., Dowd D.R., MacDonald P.N. Calmodulin-dependent kinase IV stimulates vitamin D receptor-mediated transcription. Mol. Endocrinol. 2005, 19:2309-2319.
161. 3 to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 2002, 408:200-204.
162. 3. Endocrinology 1984, 115:1476-1483.
163. 3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis nor 6-s-trans locked analogs are preferred for genomic biological responses. Mol. Endocrinol. 1997, 11:1518-1531.
164. 3 in normal human keratinocytes. J. Invest. Dermatol. 1996, 106:1212-1217.
165. 3 and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J. Steroid Biochem. Mol. Biol. 2004, 89-90:567-570.
166. 3 and its analogs. J. Steroid Biochem. & Mol. Biol. 2005, 97:137-143.
167. Peric M., Koglin S., Dombrowski Y., Gross K., Bradac E., Ruzicka T., et al. VDR and MEK-ERK dependent induction of the antimicrobial peptide cathelicidin in keratinocytes by lithocholic acid. Mol. Immunol. 2009, 46:3183-3187.
168. 3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp. Cell Res. 1996, 222:61-69.
169. 3 stimulates expression and translocation of protein kinase Cα and Cδ via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells. J. Biol. Chem. 1996, 271:16090-16096.
170. 3-26,23-lactone analogs antagonize differentiation of human leukemia cells (HL-60 cells) but not of human acute promyelocytic leukemia cells (NB4 cells). FEBS Lett. 1999, 460:297-302.
171. 3 in promyelocytic NB4 leukemia cells: a structure-function study. Endocrinology 1998, 139:457-465.
172. 3 analogs activating ERK2 in HL-60 cells show that retinoic acid-induced differentiation and cell cycle arrest require early concurrent MAPK and RAR and RXR activation. In Vitro Cell Dev. Biol. Anim. 2001, 37:93-99.
173. 3 in cardiac muscle. Mol. Cell Endocrinol. 1991, 82:229-235.
174. 3 induces arachidonate mobilization in embryonic chick myoblasts. Biochim. Biophys. Acta. Mol. Cell Res. 1993, 1179:98-104.
175. 3 metabolites modulate dihydropyridine-sensitive calcium currents in clonal rat osteosarcoma cells. J. Biol. Chem. 1989, 264:20265-20274.
176. 2+ on phospholipid metabolism in dispersed porcine parathyroid cells. Endocrinology 1990, 127:2738-2743.
177. 3 signaling in chick enterocytes: enhancement of tyrosine phosphorylation and rapid stimulation of mitogen-activated protein (MAP) kinase. J. Cell Biochem. 1998, 69:470-482.
178. Ma Y., Yu W.D., Kong R.X., Trump D.L., Johnson C.S. Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Cancer Res. 2006, 66:8131-8138.
179. 3 cytosol receptors from human and chicken intestinal mucosa. J. Clin. Endocrinol. Metab. 1980, 50:152-157.
180. Cooke N.E., Willard H.F., David E.V., George D.L. Direct regional assignment of the gene for vitamin-D binding-protein (Gc-globulin) to human chromosome 4Q11-Q13 and identification of an associated DNA polymorphism. Hum. Genet. 1986, 73:225-229.
181. Cooke N.E., Haddad J.G. Vitamin D binding protein (Gc-globulin). Endocr. Rev. 1989, 10:294-307.
182. Choi M., Yamamoto K., Masuno H., Nakashima K., Taga T., Yamada S. Ligand recognition by the vitamin D receptor. Bioorg. Med. Chem. 2001, 9:1721-1730.
183. Henry H.L. 25-(OH)D3-1α-hydroxylase. Vitamin D, Academic Press, San Diego, CA 1997, 57-68. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
184. 3-26,23-lactone in the rat. FEBS Lett. 1982, 139:267-270.
185. 3-26, 23-lactone in the rat. J. Steroid Biochem. 1984, 20:611-615.
186. 2D3-26,23-lactone. Vitamin D: Chemical, Biochemistry and Clinical Update 1985, 402-403. Walter de Gruyter, Berlin. A.W. Norman, K. Schaefer, H.-G. Grigoleit, D. von Herrath (Eds.).
187. Ando H., Mizutani A., Kiefer H., Tsuzurugi D., Michikawa T., Mikoshiba K. IRBIT suppresses IP3 receptor activity by competing with IP3 for the common binding site on the IP3 receptor. Mol. Cell 2006, 22:795-806.
188. Jirmanova L., Ashwell J.D. T cell priming: let there be light. Cell Res. 2010, 20:608-610.
189. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7:684-700.
190. Barletta F., Wong C.W., McNally C., Komm B.S., Katzenellenbogen B., Cheskis B.J. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol. Endocrinol. 2004, 18:1096-1108.
191. Biggins J.B., Koh J.T. Chemical biology of steroid and nuclear hormone receptors. Curr. Opin. Chem. Biol. 2007, 11:99-110.
192. Okamura W.H., Midland M.M., Hill D.K., Ringe K., Takeuchi J.A., Vassar V.C., et al. Vitamin D drug design and synthesis: towards understanding the "mutually induced fit" of vitamin D ligands and various proteins which bind metabolites and analogs. Vitamin D 1997, 11-18. Chemistry, Biology and Clinical Applications of the Steroid Hormone. Riverside, CA: University of California, Riverside. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).